1
|
Minnes GL, Wiener AJ, Liley AE, Simon NW. Dopaminergic modulation of sensitivity to immediate and delayed punishment during decision-making. COGNITIVE, AFFECTIVE & BEHAVIORAL NEUROSCIENCE 2024; 24:304-321. [PMID: 38052746 DOI: 10.3758/s13415-023-01139-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/01/2023] [Indexed: 12/07/2023]
Abstract
Effective decision-making involves careful consideration of all rewarding and aversive outcomes. Importantly, negative outcomes often occur later in time, leading to underestimation, or "discounting," of these consequences. Despite the frequent occurrence of delayed outcomes, little is known about the neurobiology underlying sensitivity to delayed punishment during decision-making. The Delayed Punishment Decision-making Task (DPDT) addresses this by assessing sensitivity to delayed versus immediate punishment in rats. Rats initially avoid punished reinforcers, then select this option more frequently when delay precedes punishment. We used DPDT to examine effects of acute systemic administration of catecholaminergic drugs on sensitivity to delayed punishment in male and female adult rats. Cocaine did not affect choice of rewards with immediate punishment but caused a dose-dependent reduction in choice of delayed punishment. Neither activation nor blockade of D1-like dopamine receptor affected decision-making, but activation of D2-like dopamine receptors reduced choice of delayed punishment. D2 blockade did not attenuate cocaine's effects on decision-making, suggesting that cocaine's effects are not dependent on D2 receptor activation. Increasing synaptic norepinephrine via atomoxetine also reduced choice of delayed (but not immediate) punishment. Notably, when DPDT was modified from ascending to descending pre-punishment delays, these drugs did not affect choice of delayed or immediate punishment, although high-dose quinpirole impaired behavioral flexibility. In summary, sensitivity to delayed punishment is regulated by both dopamine and norepinephrine transmission in task-specific fashion. Understanding the neurochemical modulation of decision-making with delayed punishment is a critical step toward treating disorders characterized by aberrant sensitivity to negative consequences.
Collapse
Affiliation(s)
- Grace L Minnes
- Department of Psychology, University of Memphis, Memphis, TN, USA
| | - Anna J Wiener
- Department of Psychology, University of Memphis, Memphis, TN, USA
| | - Anna E Liley
- Department of Psychology, University of Memphis, Memphis, TN, USA
| | - Nicholas W Simon
- Department of Psychology, University of Memphis, Memphis, TN, USA.
| |
Collapse
|
2
|
Massaccesi C, Korb S, Götzendorfer S, Chiappini E, Willeit M, Lundström JN, Windischberger C, Eisenegger C, Silani G. Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards. Hum Brain Mapp 2024; 45:e26645. [PMID: 38445523 PMCID: PMC10915723 DOI: 10.1002/hbm.26645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Revised: 02/01/2024] [Accepted: 02/19/2024] [Indexed: 03/07/2024] Open
Abstract
Rewards are a broad category of stimuli inducing approach behavior to aid survival. Extensive evidence from animal research has shown that wanting (the motivation to pursue a reward) and liking (the pleasure associated with its consumption) are mostly regulated by dopaminergic and opioidergic activity in dedicated brain areas. However, less is known about the neuroanatomy of dopaminergic and opioidergic regulation of reward processing in humans, especially when considering different types of rewards (i.e., social and nonsocial). To fill this gap of knowledge, we combined dopaminergic and opioidergic antagonism (via amisulpride and naltrexone administration) with functional neuroimaging to investigate the neurochemical and neuroanatomical bases of wanting and liking of matched nonsocial (food) and social (interpersonal touch) rewards, using a randomized, between-subject, placebo-controlled, double-blind design. While no drug effect was observed at the behavioral level, brain activity was modulated by the administered compounds. In particular, opioid antagonism, compared to placebo, reduced activity in the medial orbitofrontal cortex during consumption of the most valued social and nonsocial rewards. Dopamine antagonism, however, had no clear effects on brain activity in response to reward anticipation. These findings provide insights into the neurobiology of human reward processing and suggest a similar opioidergic regulation of the neural responses to social and nonsocial reward consumption.
Collapse
Affiliation(s)
- Claudia Massaccesi
- Department of Clinical and Health PsychologyUniversity of ViennaViennaAustria
- Department of Cognition, Emotion and Methods in PsychologyUniversity of ViennaViennaAustria
| | - Sebastian Korb
- Department of Cognition, Emotion and Methods in PsychologyUniversity of ViennaViennaAustria
- Department of PsychologyUniversity of EssexColchesterUK
| | | | - Emilio Chiappini
- Department of Clinical and Health PsychologyUniversity of ViennaViennaAustria
| | - Matthaeus Willeit
- Department of Psychiatry and PsychotherapyMedical University of ViennaViennaAustria
| | | | - Christian Windischberger
- MR Center of Excellence, Center for Medical Physics and Biomedical EngineeringMedical University of ViennaViennaAustria
| | - Christoph Eisenegger
- Department of Cognition, Emotion and Methods in PsychologyUniversity of ViennaViennaAustria
| | - Giorgia Silani
- Department of Clinical and Health PsychologyUniversity of ViennaViennaAustria
| |
Collapse
|
3
|
Chong TTJ, Fortunato E, Bellgrove MA. Amphetamines Improve the Motivation to Invest Effort in Attention-Deficit/Hyperactivity Disorder. J Neurosci 2023; 43:6898-6908. [PMID: 37666665 PMCID: PMC10573750 DOI: 10.1523/jneurosci.0982-23.2023] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2023] [Revised: 07/26/2023] [Accepted: 07/31/2023] [Indexed: 09/06/2023] Open
Abstract
Prevailing frameworks propose that a key feature of attention-deficit/hyperactivity disorder (ADHD) is lower motivation. An important component of motivation is the willingness to engage in cognitively or physically effortful behavior. However, the degree to which effort sensitivity is impaired in ADHD has rarely been tested, and the efficacy of stimulant medication in ameliorating any such impairments is unclear. Here, we tested 20 individuals with ADHD (11 males, 9 females) who were managed with amphetamine-based medication (dexamfetamine, lisdexamfetamine), and 24 controls (8 males, 16 females). Individuals with ADHD were tested over two counterbalanced sessions, ON and OFF their usual amphetamine-based medication. In each session, participants performed an effort-based decision-making task, in which they were required to choose how much cognitive or physical effort they were willing to engage in return for reward. Our results revealed three main findings. First, individuals with ADHD had lower motivation relative to controls to invest effort in both the cognitive and physical domains. Second, amphetamine increased motivation uniformly across both domains. Finally, the net effect of amphetamine treatment was to mostly restore motivation across both domains of effort relative to healthy controls. These data provide clear evidence for a heightened sensitivity to both cognitive and physical effort in ADHD, and reveal the efficacy of amphetamine-based drugs in restoring effort sensitivity to levels similar to controls. These findings confirm the existence of reduced motivational drive in ADHD, and more broadly provide direct causal evidence for a domain-general role of catecholamines in motivating effortful behavior.SIGNIFICANCE STATEMENT A core feature of attention-deficit/hyperactivity disorder (ADHD) is thought to be a heightened aversion to effort. Surprisingly, however, the degree to which effort sensitivity is impaired in ADHD has rarely been tested. More broadly, the relative efficacy of catecholamines in motivating the investment of cognitive and physical effort is unclear. We tested 20 individuals with ADHD ON and OFF amphetamines, and compared their behavior on an effort-based decision-making task to 24 controls. When tested OFF medication, the ADHD group was less cognitively and physically motivated than controls. However, amphetamines led to a comparable increase in motivation across both domains. This demonstrates the efficacy of catecholamines in facilitating domain-general effort, and highlights the broader potential of such drugs to treat disorders of motivation.
Collapse
Affiliation(s)
- Trevor T-J Chong
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria 3800, Australia
- Department of Neurology, Alfred Health, Melbourne, Victoria 3004, Australia
- Department of Clinical Neurosciences, St Vincent's Hospital, Melbourne, Victoria 3065, Australia
| | - Erika Fortunato
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria 3800, Australia
| | - Mark A Bellgrove
- Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, Victoria 3800, Australia
| |
Collapse
|
4
|
Kwon M, Lee SH, Ahn WY. Adaptive Design Optimization as a Promising Tool for Reliable and Efficient Computational Fingerprinting. BIOLOGICAL PSYCHIATRY. COGNITIVE NEUROSCIENCE AND NEUROIMAGING 2023; 8:798-804. [PMID: 36805245 DOI: 10.1016/j.bpsc.2022.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 11/21/2022] [Accepted: 12/11/2022] [Indexed: 12/23/2022]
Abstract
A key challenge in understanding mental (dys)functions is their etiological and functional heterogeneity, and several multidimensional assessments have been proposed for their comprehensive characterization. However, such assessments require lengthy testing, which may hinder reliable and efficient characterization of individual differences due to increased fatigue and distraction, especially in clinical populations. Computational modeling may address this challenge as it often provides more reliable measures of latent neurocognitive processes underlying observed behaviors and captures individual differences better than traditional assessments. However, even with a state-of-the-art hierarchical modeling approach, reliable estimation of model parameters still requires a large number of trials. Recent work suggests that Bayesian adaptive design optimization (ADO) is a promising way to address these challenges. With ADO, experimental design is optimized adaptively from trial to trial to extract the maximum amount of information about an individual's characteristics. In this review, we first describe the ADO methodology and then summarize recent work demonstrating that ADO increases the reliability and efficiency of latent neurocognitive measures. We conclude by discussing the challenges and future directions of ADO and proposing development of ADO-based computational fingerprints to reliably and efficiently characterize the heterogeneous profiles of psychiatric disorders.
Collapse
Affiliation(s)
- Mina Kwon
- Department of Psychology, Seoul National University, Seoul, Korea
| | - Sang Ho Lee
- Department of Psychology, Seoul National University, Seoul, Korea; Department of Brain and Cognitive Sciences, Seoul National University, Seoul, Korea
| | - Woo-Young Ahn
- Department of Psychology, Seoul National University, Seoul, Korea; Department of Brain and Cognitive Sciences, Seoul National University, Seoul, Korea.
| |
Collapse
|
5
|
Soutschek A, Tobler PN. A process model account of the role of dopamine in intertemporal choice. eLife 2023; 12:83734. [PMID: 36884013 PMCID: PMC9995109 DOI: 10.7554/elife.83734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Accepted: 02/27/2023] [Indexed: 03/09/2023] Open
Abstract
Theoretical accounts disagree on the role of dopamine in intertemporal choice and assume that dopamine either promotes delay of gratification by increasing the preference for larger rewards or that dopamine reduces patience by enhancing the sensitivity to waiting costs. Here, we reconcile these conflicting accounts by providing empirical support for a novel process model according to which dopamine contributes to two dissociable components of the decision process, evidence accumulation and starting bias. We re-analyzed a previously published data set where intertemporal decisions were made either under the D2 antagonist amisulpride or under placebo by fitting a hierarchical drift diffusion model that distinguishes between dopaminergic effects on the speed of evidence accumulation and the starting point of the accumulation process. Blocking dopaminergic neurotransmission not only strengthened the sensitivity to whether a reward is perceived as worth the delay costs during evidence accumulation (drift rate) but also attenuated the impact of waiting costs on the starting point of the evidence accumulation process (bias). In contrast, re-analyzing data from a D1 agonist study provided no evidence for a causal involvement of D1R activation in intertemporal choices. Taken together, our findings support a novel, process-based account of the role of dopamine for cost-benefit decision making, highlight the potential benefits of process-informed analyses, and advance our understanding of dopaminergic contributions to decision making.
Collapse
Affiliation(s)
| | - Philippe N Tobler
- Zurich Center for Neuroeconomics, Department of Economics, University of ZurichZürichSwitzerland
- Neuroscience Center Zurich, University of Zurich, Swiss Federal Institute of Technology ZurichZurichSwitzerland
| |
Collapse
|
6
|
Soutschek A, Bulley A, Wittekind CE. Metacognitive deficits are associated with lower sensitivity to preference reversals in nicotine dependence. Sci Rep 2022; 12:19787. [PMID: 36396945 PMCID: PMC9671892 DOI: 10.1038/s41598-022-24332-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 11/14/2022] [Indexed: 11/19/2022] Open
Abstract
Deficits in impulse control belong to the core profile of nicotine dependence. Smokers might thus benefit from voluntarily self-restricting their access to the immediate temptation of nicotine products (precommitment) in order to avoid impulse control failures. However, little is known about how smokers' willingness to engage in voluntary self-restrictions is determined by metacognitive insight into their general preferences for immediate over delayed rewards. Here, with a series of monetary intertemporal choice tasks, we provide empirical evidence for reduced metacognitive accuracy in smokers relative to non-smokers and show that smokers overestimate the subjective value of delayed rewards relative to their revealed preferences. In line with the metacognitive deficits, smokers were also less sensitive to the risk of preference reversals when deciding whether or not to restrict their access to short-term financial rewards. Taken together, the current findings suggest that deficits not only in impulse control but also in metacognition may hamper smokers' resistance to immediate rewards and capacity to pursue long-term goals.
Collapse
Affiliation(s)
- Alexander Soutschek
- grid.5252.00000 0004 1936 973XChair of Experimental and General Psychology, Department of Psychology, Ludwig Maximilian University Munich, Leopoldstr. 13, 80802 Munich, Germany
| | - Adam Bulley
- grid.1013.30000 0004 1936 834XThe University of Sydney, School of Psychology and Brain and Mind Centre, Sydney, Australia ,grid.38142.3c000000041936754XDepartment of Psychology, Harvard University, Cambridge, USA
| | - Charlotte E. Wittekind
- grid.5252.00000 0004 1936 973XChair of Clinical Psychology, Department of Psychology, Ludwig Maximilian University Munich, Munich, Germany
| |
Collapse
|
7
|
Dennison JB, Sazhin D, Smith DV. Decision neuroscience and neuroeconomics: Recent progress and ongoing challenges. WILEY INTERDISCIPLINARY REVIEWS. COGNITIVE SCIENCE 2022; 13:e1589. [PMID: 35137549 PMCID: PMC9124684 DOI: 10.1002/wcs.1589] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Revised: 11/28/2021] [Accepted: 12/21/2021] [Indexed: 01/10/2023]
Abstract
In the past decade, decision neuroscience and neuroeconomics have developed many new insights in the study of decision making. This review provides an overarching update on how the field has advanced in this time period. Although our initial review a decade ago outlined several theoretical, conceptual, methodological, empirical, and practical challenges, there has only been limited progress in resolving these challenges. We summarize significant trends in decision neuroscience through the lens of the challenges outlined for the field and review examples where the field has had significant, direct, and applicable impacts across economics and psychology. First, we review progress on topics including reward learning, explore-exploit decisions, risk and ambiguity, intertemporal choice, and valuation. Next, we assess the impacts of emotion, social rewards, and social context on decision making. Then, we follow up with how individual differences impact choices and new exciting developments in the prediction and neuroforecasting of future decisions. Finally, we consider how trends in decision-neuroscience research reflect progress toward resolving past challenges, discuss new and exciting applications of recent research, and identify new challenges for the field. This article is categorized under: Psychology > Reasoning and Decision Making Psychology > Emotion and Motivation.
Collapse
Affiliation(s)
- Jeffrey B Dennison
- Department of Psychology, Temple University, Philadelphia, Pennsylvania, USA
| | - Daniel Sazhin
- Department of Psychology, Temple University, Philadelphia, Pennsylvania, USA
| | - David V Smith
- Department of Psychology, Temple University, Philadelphia, Pennsylvania, USA
| |
Collapse
|
8
|
Soutschek A, Jetter A, Tobler PN. Towards a Unifying Account of Dopamine’s Role in Cost-Benefit Decision Making. BIOLOGICAL PSYCHIATRY GLOBAL OPEN SCIENCE 2022; 3:179-186. [PMID: 37124350 PMCID: PMC10140448 DOI: 10.1016/j.bpsgos.2022.02.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/25/2022] [Accepted: 02/25/2022] [Indexed: 10/18/2022] Open
Abstract
Dopamine is thought to play a crucial role in cost-benefit decision making, but so far there is no consensus on the precise role of dopamine in decision making. Here, we review the literature on dopaminergic manipulations of cost-benefit decision making in humans and evaluate how well different theoretical accounts explain the existing body of evidence. Reduced D2 stimulation tends to increase the willingness to bear delay and risk costs (i.e., wait for later rewards, take riskier options), while increased D1 and D2 receptor stimulation increases willingness to bear effort costs. We argue that the empirical findings can best be explained by combining the strengths of two theoretical accounts: in cost-benefit decision making, dopamine may play a dual role both in promoting the pursuit of psychologically close options (e.g., sooner and safer rewards) and in computing which costs are acceptable for a reward at stake. Moreover, we identify several limiting factors in the study designs of previous investigations that prevented a fuller understanding of dopamine's role in value-based choice. Together, the proposed theoretical framework and the methodological suggestions for future studies may bring us closer to a unifying account of dopamine in healthy and impaired cost-benefit decision making.
Collapse
|
9
|
Jones-Tabah J, Mohammad H, Paulus EG, Clarke PBS, Hébert TE. The Signaling and Pharmacology of the Dopamine D1 Receptor. Front Cell Neurosci 2022; 15:806618. [PMID: 35110997 PMCID: PMC8801442 DOI: 10.3389/fncel.2021.806618] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 12/23/2021] [Indexed: 12/30/2022] Open
Abstract
The dopamine D1 receptor (D1R) is a Gαs/olf-coupled GPCR that is expressed in the midbrain and forebrain, regulating motor behavior, reward, motivational states, and cognitive processes. Although the D1R was initially identified as a promising drug target almost 40 years ago, the development of clinically useful ligands has until recently been hampered by a lack of suitable candidate molecules. The emergence of new non-catechol D1R agonists, biased agonists, and allosteric modulators has renewed clinical interest in drugs targeting this receptor, specifically for the treatment of motor impairment in Parkinson's Disease, and cognitive impairment in neuropsychiatric disorders. To develop better therapeutics, advances in ligand chemistry must be matched by an expanded understanding of D1R signaling across cell populations in the brain, and in disease states. Depending on the brain region, the D1R couples primarily to either Gαs or Gαolf through which it activates a cAMP/PKA-dependent signaling cascade that can regulate neuronal excitability, stimulate gene expression, and facilitate synaptic plasticity. However, like many GPCRs, the D1R can signal through multiple downstream pathways, and specific signaling signatures may differ between cell types or be altered in disease. To guide development of improved D1R ligands, it is important to understand how signaling unfolds in specific target cells, and how this signaling affects circuit function and behavior. In this review, we provide a summary of D1R-directed signaling in various neuronal populations and describe how specific pathways have been linked to physiological and behavioral outcomes. In addition, we address the current state of D1R drug development, including the pharmacology of newly developed non-catecholamine ligands, and discuss the potential utility of D1R-agonists in Parkinson's Disease and cognitive impairment.
Collapse
|
10
|
Brain stimulation over dorsomedial prefrontal cortex modulates effort-based decision making. COGNITIVE, AFFECTIVE & BEHAVIORAL NEUROSCIENCE 2022; 22:1264-1274. [PMID: 35729467 PMCID: PMC9622516 DOI: 10.3758/s13415-022-01021-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Accepted: 06/11/2022] [Indexed: 01/27/2023]
Abstract
Deciding whether to engage in strenuous mental activities requires trading-off the potential benefits against the costs of mental effort, but it is unknown which brain rhythms are causally involved in such cost-benefit calculations. We show that brain stimulation targeting midfrontal theta oscillations increases the engagement in goal-directed mental effort. Participants received transcranial alternating current stimulation over dorsomedial prefrontal cortex while deciding whether they are willing to perform a demanding working memory task for monetary rewards. Midfrontal theta tACS increased the willingness to exert mental effort for rewards while leaving working memory performance unchanged. Computational modelling using a hierarchical Bayesian drift diffusion model suggests that theta tACS shifts the starting bias before evidence accumulation towards high reward-high effort options without affecting the velocity of the evidence accumulation process. Our findings suggest that the motivation to engage in goal-directed mental effort can be increased via midfrontal tACS.
Collapse
|
11
|
Veselinović T, Neuner I. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 2022; 36:819-858. [PMID: 35831706 PMCID: PMC9345797 DOI: 10.1007/s40263-022-00935-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/06/2022] [Indexed: 12/11/2022]
Abstract
Cognitive impairments associated with schizophrenia (CIAS) represent a central element of the symptomatology of this severe mental disorder. CIAS substantially determine the disease prognosis and hardly, if at all, respond to treatment with currently available antipsychotics. Remarkably, all drugs presently approved for the treatment of schizophrenia are, to varying degrees, dopamine D2/D3 receptor blockers. In turn, rapidly growing evidence suggests the immense significance of systems other than the dopaminergic system in the genesis of CIAS. Accordingly, current efforts addressing the unmet needs of patients with schizophrenia are primarily based on interventions in other non-dopaminergic systems. In this review article, we provide a brief overview of the available evidence on the importance of specific systems in the development of CIAS. In addition, we describe the promising targets for the development of new drugs that have been used so far. In doing so, we present the most important candidates that have been investigated in the field of the specific systems in recent years and present a summary of the results available at the time of drafting this review (May 2022), as well as the currently ongoing studies.
Collapse
Affiliation(s)
- Tanja Veselinović
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
- Institute of Neuroscience and Medicine 4, INM-4, Forschungszentrum Jülich, Jülich, Germany.
| | - Irene Neuner
- Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany
- Institute of Neuroscience and Medicine 4, INM-4, Forschungszentrum Jülich, Jülich, Germany
- JARA-BRAIN, Aachen, Germany
| |
Collapse
|
12
|
Moore TL, Young DA, Killiany RJ, Fonseca KR, Volfson D, Gray DL, Balice-Gordon R, Kozak R. The Effects of a Novel Non-catechol Dopamine Partial Agonist on Working Memory in the Aged Rhesus Monkey. Front Aging Neurosci 2021; 13:757850. [PMID: 34899271 PMCID: PMC8662559 DOI: 10.3389/fnagi.2021.757850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Accepted: 10/23/2021] [Indexed: 11/13/2022] Open
Abstract
Aged-related declines in cognition, especially working memory and executive function, begin in middle-age and these abilities are known to be mediated by the prefrontal cortex (PFC) and more specifically the dopamine (DA) system within the PFC. In both humans and monkeys, there is significant evidence that the PFC is the first cortical region to change with age and the PFC appears to be particularly vulnerable to age-related loss of dopamine (DA). Therefore, the DA system is a strong candidate for therapeutic intervention to slow or reverse age related declines in cognition. In the present study, we administered a novel selective, potent, non-catechol DA D1 R agonist PF-6294 (Pfizer, Inc.) to aged female rhesus monkeys and assessed their performance on two benchmark tasks of working memory - the Delayed Non-match to Sample Task (DNMS) and Delayed Recognition Span Task (DRST). The DNMS task was administered first with the standard 10 s delay and then with 5 min delays, with and without distractors. The DRST was administered each day with four trials with unique sequences and one trial of a repeated sequence to assess evidence learning and retention. Overall, there was no significant effect of drug on performance on any aspect of the DNMS task. In contrast, we demonstrated that a middle range dose of PF-6294 significantly increased memory span on the DRST on the first and last days of testing and by the last day of testing the increased memory span was driven by the performance on the repeated trials.
Collapse
Affiliation(s)
- Tara L Moore
- Department of Anatomy & Neurobiology, Boston University School of Medicine, Boston, MA, United States.,Center for Systems Neuroscience, Boston University, Boston, MA, United States
| | - Damon A Young
- Internal Medicine Research Unit Pfizer Worldwide Research, Development and Medical Pfizer Inc., Cambridge, MA, United States
| | - Ronald J Killiany
- Department of Anatomy & Neurobiology, Boston University School of Medicine, Boston, MA, United States.,Center for Systems Neuroscience, Boston University, Boston, MA, United States
| | - Kari R Fonseca
- Medicine Design, Pfizer Worldwide Research, Development and Medical Pfizer Inc., Cambridge, MA, United States
| | - Dmitri Volfson
- Internal Medicine Research Unit Pfizer Worldwide Research, Development and Medical Pfizer Inc., Cambridge, MA, United States
| | - David L Gray
- Internal Medicine Research Unit Pfizer Worldwide Research, Development and Medical Pfizer Inc., Cambridge, MA, United States
| | - Rita Balice-Gordon
- Internal Medicine Research Unit Pfizer Worldwide Research, Development and Medical Pfizer Inc., Cambridge, MA, United States
| | - Rouba Kozak
- Internal Medicine Research Unit Pfizer Worldwide Research, Development and Medical Pfizer Inc., Cambridge, MA, United States
| |
Collapse
|
13
|
Soutschek A, Weber SC, Kahnt T, Quednow BB, Tobler PN. Opioid antagonism modulates wanting-related frontostriatal connectivity. eLife 2021; 10:71077. [PMID: 34761749 PMCID: PMC8598157 DOI: 10.7554/elife.71077] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 11/10/2021] [Indexed: 02/06/2023] Open
Abstract
Theoretical accounts distinguish between motivational (‘wanting’) and hedonic (‘liking’) dimensions of rewards. Previous animal and human research linked wanting and liking to anatomically and neurochemically distinct brain mechanisms, but it remains unknown how the different brain regions and neurotransmitter systems interact in processing distinct reward dimensions. Here, we assessed how pharmacological manipulations of opioid and dopamine receptor activation modulate the neural processing of wanting and liking in humans in a randomized, placebo-controlled, double-blind clinical trial. Reducing opioid receptor activation with naltrexone selectively reduced wanting of rewards, which on a neural level was reflected by stronger coupling between dorsolateral prefrontal cortex and the striatum under naltrexone compared with placebo. In contrast, reducing dopaminergic neurotransmission with amisulpride revealed no robust effects on behavior or neural activity. Our findings thus provide insights into how opioid receptors mediate neural connectivity related to specifically motivational, not hedonic, aspects of rewards.
Collapse
Affiliation(s)
| | - Susanna C Weber
- Zurich Center for Neuroeconomics, Department of Economics, University of Zurich, Zürich, Switzerland
| | - Thorsten Kahnt
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, United States
| | - Boris B Quednow
- Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.,Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zürich, Switzerland
| | - Philippe N Tobler
- Zurich Center for Neuroeconomics, Department of Economics, University of Zurich, Zürich, Switzerland.,Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Zürich, Switzerland
| |
Collapse
|
14
|
Prettyman GE, Kable JW, Didier P, Shankar S, Satterthwaite TD, Davatzikos C, Bilker WB, Elliott MA, Ruparel K, Wolf DH. Relationship of ventral striatum activation during effort discounting to clinical amotivation severity in schizophrenia. NPJ SCHIZOPHRENIA 2021; 7:48. [PMID: 34625567 PMCID: PMC8501117 DOI: 10.1038/s41537-021-00178-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Accepted: 09/17/2021] [Indexed: 12/04/2022]
Abstract
Motivational deficits play a central role in disability due to negative symptoms of schizophrenia (SZ), but limited pathophysiological understanding impedes critically needed therapeutic development. We applied an fMRI Effort Discounting Task (EDT) that quantifies motivation using a neuroeconomic decision-making approach, capturing the degree to which effort requirements produce reductions in the subjective value (SV) of monetary reward. An analyzed sample of 21 individuals with SZ and 23 group-matched controls performed the EDT during fMRI. We hypothesized that ventral striatum (VS) as well as extended brain motivation circuitry would encode SV, integrating reward and effort costs. We also hypothesized that VS hypoactivation during EDT decisions would demonstrate a dimensional relationship with clinical amotivation severity, reflecting greater suppression by effort costs. As hypothesized, VS as well as a broader cortico-limbic network were activated during the EDT and this activation correlated positively with SV. In SZ, activation to task decisions was reduced selectively in VS. Greater VS reductions correlated with more severe clinical amotivation in SZ and across all participants. However, these diagnosis and amotivation effects could not be explained by the response to parametric variation in reward, effort, or model-based SV. Our findings demonstrate that VS hypofunction in schizophrenia is manifested during effort-based decisions and reflects dimensional motivation impairment. Dysfunction of VS impacting effort-based decision-making can provide a target for biomarker development to guide novel efforts to assess and treat disabling amotivation.
Collapse
Affiliation(s)
- Greer E Prettyman
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA.
| | - Joseph W Kable
- Department of Psychology, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Paige Didier
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Sheila Shankar
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Theodore D Satterthwaite
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Penn Lifespan Informatics and Neuroimaging Center, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Christos Davatzikos
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Warren B Bilker
- Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Mark A Elliott
- Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Kosha Ruparel
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Daniel H Wolf
- Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, PA, 19104, USA
| |
Collapse
|
15
|
Hess TM, Freund AM, Tobler PN. Effort Mobilization and Healthy Aging. J Gerontol B Psychol Sci Soc Sci 2021; 76:S135-S144. [PMID: 34515772 DOI: 10.1093/geronb/gbab030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Indexed: 12/29/2022] Open
Abstract
Healthy aging is in part dependent upon people's willingness and ability to mobilize the effort necessary to support behaviors that promote health and well-being. People may have the best information relating to health along with the best intentions to stay healthy (e.g., health-related goals), but positive outcomes will ultimately be dependent upon them actually investing the necessary effort toward using this information to achieve their goals. In addition, the influences on effort mobilization may vary as a function of physical, psychological, and social changes experienced by the individual across the life span. Building on the overall theme of this special issue, we explore the relationships between motivation, effort mobilization, and healthy aging. We begin by characterizing the relationship between motivation and effort, and identify the factors that influence effort mobilization. We then consider the factors associated specifically with aging that may influence effort mobilization (e.g., changes in cardiovascular and neural mechanisms) and, ultimately, the health and well-being of older adults. Finally, distinguishing between those influential factors that are modifiable versus intractable, we identify ways to structure situations and beliefs to optimize mobilization in support of healthy aging.
Collapse
Affiliation(s)
- Thomas M Hess
- Department of Psychology, North Carolina State University, Raleigh, USA
| | - Alexandra M Freund
- Department of Psychology and University Research Priority Program "Dynamics of Healthy Aging," University of Zurich, Switzerland.,National Centre of Competence in Research (NCCR) LIVES, Zurich, Switzerland
| | | |
Collapse
|
16
|
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophr Bull 2021; 48:199-210. [PMID: 34423843 PMCID: PMC8781338 DOI: 10.1093/schbul/sbab095] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Decades of research have highlighted the importance of optimal stimulation of cortical dopaminergic receptors, particularly the D1R receptor (D1R), for prefrontal-mediated cognition. This mechanism is particularly relevant to the cognitive deficits in schizophrenia, given the abnormalities in cortical dopamine (DA) neurotransmission and in the expression of D1R. Despite the critical need for D1R-based therapeutics, many factors have complicated their development and prevented this important therapeutic target from being adequately interrogated. Challenges include determination of the optimal level of D1R stimulation needed to improve cognitive performance, especially when D1R expression levels, affinity states, DA levels, and the resulting D1R occupancy by DA, are not clearly known in schizophrenia, and may display great interindividual and intraindividual variability related to cognitive states and other physiological variables. These directly affect the selection of the level of stimulation necessary to correct the underlying neurobiology. The optimal mechanism for stimulation is also unknown and could include partial or full agonism, biased agonism, or positive allosteric modulation. Furthermore, the development of D1R targeting drugs has been complicated by complexities in extrapolating from in vitro affinity determinations to in vivo use. Prior D1R-targeted drugs have been unsuccessful due to poor bioavailability, pharmacokinetics, and insufficient target engagement at tolerable doses. Newer drugs have recently become available, and these must be tested in the context of carefully designed paradigms that address methodological challenges. In this paper, we discuss how a better understanding of these challenges has shaped our proposed experimental design for testing a new D1R/D5R partial agonist, PF-06412562, renamed CVL-562.
Collapse
Affiliation(s)
- Anissa Abi-Dargham
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA,Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA,Department of Psychiatry, Yale University, New Haven, CT, USA,Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA,Cerevel Therapeutics Research and Development, Boston, MA, USA,To whom correspondence should be addressed; Tel: +(631) 885-0814; e-mail:
| | - Jonathan A Javitch
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Mark Slifstein
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA
| | - Alan Anticevic
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Monica E Calkins
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Youngsun T Cho
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Clara Fonteneau
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Roberto Gil
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA
| | - Ragy Girgis
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Raquel E Gur
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Ruben C Gur
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Jack Grinband
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Joshua Kantrowitz
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| | - Christian Kohler
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - John Krystal
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - John Murray
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | | | | | - Jared Van Snellenberg
- Department of Psychiatry, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA
| | - Zailyn Tamayo
- Department of Psychiatry, Yale University, New Haven, CT, USA
| | - Daniel Wolf
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | | | - David Gray
- Cerevel Therapeutics Research and Development, Boston, MA, USA
| | - Jeffrey Lieberman
- Department of Psychiatry, New York State Psychaitric Institute, Columbia University, New York, NY, USA
| |
Collapse
|
17
|
Kapetaniou GE, Reinhard MA, Christian P, Jobst A, Tobler PN, Padberg F, Soutschek A. The role of oxytocin in delay of gratification and flexibility in non-social decision making. eLife 2021; 10:e61844. [PMID: 33821797 PMCID: PMC8024008 DOI: 10.7554/elife.61844] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2020] [Accepted: 03/24/2021] [Indexed: 01/03/2023] Open
Abstract
Oxytocin is well-known for its impact on social cognition. This specificity for the social domain, however, has been challenged by findings suggesting a domain-general allostatic function for oxytocin by promoting future-oriented and flexible behavior. In this pre-registered study, we tested the hypothesized domain-general function of oxytocin by assessing the impact of intranasal oxytocin (24 IU) on core aspects of human social (inequity aversion) and non-social decision making (delay of gratification and cognitive flexibility) in 49 healthy volunteers (within-subject design). In intertemporal choice, patience was higher under oxytocin than under placebo, although this difference was evident only when restricting the analysis to the first experimental session (between-group comparison) due to carry-over effects. Further, oxytocin increased cognitive flexibility in reversal learning as well as generosity under conditions of advantageous but not disadvantageous inequity. Our findings show that oxytocin affects both social and non-social decision making, supporting theoretical accounts of domain-general functions of oxytocin.
Collapse
Affiliation(s)
- Georgia Eleni Kapetaniou
- Department of Psychology, Ludwig Maximilian University MunichMunichGermany
- Graduate School for Systemic Neurosciences, Department of Biology, Ludwig Maximilian University MunichMunichGermany
| | - Matthias A Reinhard
- Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University MunichMunichGermany
| | - Patricia Christian
- Department of Psychology, Ludwig Maximilian University MunichMunichGermany
- Graduate School for Systemic Neurosciences, Department of Biology, Ludwig Maximilian University MunichMunichGermany
| | - Andrea Jobst
- Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University MunichMunichGermany
| | - Philippe N Tobler
- Zurich Center for Neuroeconomics, Department of Economics, University of ZurichZurichSwitzerland
- Neuroscience Center Zurich, University of Zurich, Swiss Federal Institute of Technology ZurichZurichSwitzerland
| | - Frank Padberg
- Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University MunichMunichGermany
| | - Alexander Soutschek
- Department of Psychology, Ludwig Maximilian University MunichMunichGermany
- Graduate School for Systemic Neurosciences, Department of Biology, Ludwig Maximilian University MunichMunichGermany
| |
Collapse
|
18
|
Gabriel DBK, Liley AE, Freels TG, Simon NW. Dopamine receptors regulate preference between high-effort and high-risk rewards. Psychopharmacology (Berl) 2021; 238:991-1004. [PMID: 33410986 DOI: 10.1007/s00213-020-05745-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 12/01/2020] [Indexed: 01/02/2023]
Abstract
RATIONALE Optimal decision-making necessitates evaluation of multiple rewards that are each offset by distinct costs, such as high effort requirement or high risk of failure. The neurotransmitter dopamine is fundamental toward these cost-benefit analyses, and D1-like and D2-like dopamine receptors differently modulate the reward-discounting effects of both effort and risk. However, measuring the role of dopamine in regulating decision-making between options associated with distinct costs exceeds the scope of traditional rodent economic decision-making paradigms. OBJECTIVES We developed the effort vs probability economic conflict task (EvP) to model multimodal economic decision-making in rats. This task measures choice between two rewards of uniform magnitude associated with either a high effort requirement or risk of reward omission. We then tested the modulatory effects of systemic cocaine and D1/D2 blockade or activation on the preference between high-effort and high-risk alternatives. METHODS In the EvP, two reinforcers of equal magnitude are associated with either (1) an effort requirement that increases throughout the session (1, 5, 10, and 20 lever presses), or (2) a low probability of reward receipt (25% of probabilistic choices). Critically, the reinforcer for each choice is comparable (one pellet), which eliminates the influence of magnitude discrimination on the decision-making process. After establishing the task, the dopamine transporter blocker cocaine and D1/D2 antagonists and agonists were administered prior to EvP performance. RESULTS Preference shifted away from either effortful or probabilistic choice when either option became more costly, and this preference was highly variable between subjects and stable over time. Cocaine, D1 activation, and D2 blockade produced limited, dose-dependent shifts in choice preference contingent on high or low effort conditions. In contrast, D2 activation across multiple doses evoked a robust shift from effortful to risky choice that was evident even when clearly disadvantageous. CONCLUSIONS The EvP clearly demonstrates that rats can evaluate distinct effortful or risky costs associated with rewards of comparable magnitude, and shift preference away from either option with increasing cost. This preference is more tightly linked to D2 than D1 receptor manipulation, suggesting D2-like receptors as a possible therapeutic target for maladaptive biases toward risk-taking over effort.
Collapse
Affiliation(s)
- Daniel B K Gabriel
- Department of Psychology, University of Memphis, 400 Innovation Drive, Memphis, TN, 38112, USA
| | - Anna E Liley
- Department of Psychology, University of Memphis, 400 Innovation Drive, Memphis, TN, 38112, USA
| | - Timothy G Freels
- Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, 55 N Lake Ave, Worcester, MA, 01655, USA
| | - Nicholas W Simon
- Department of Psychology, University of Memphis, 400 Innovation Drive, Memphis, TN, 38112, USA.
| |
Collapse
|
19
|
Dubois M, Habicht J, Michely J, Moran R, Dolan RJ, Hauser TU. Human complex exploration strategies are enriched by noradrenaline-modulated heuristics. eLife 2021; 10:e59907. [PMID: 33393461 PMCID: PMC7815309 DOI: 10.7554/elife.59907] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 01/03/2021] [Indexed: 01/15/2023] Open
Abstract
An exploration-exploitation trade-off, the arbitration between sampling a lesser-known against a known rich option, is thought to be solved using computationally demanding exploration algorithms. Given known limitations in human cognitive resources, we hypothesised the presence of additional cheaper strategies. We examined for such heuristics in choice behaviour where we show this involves a value-free random exploration, that ignores all prior knowledge, and a novelty exploration that targets novel options alone. In a double-blind, placebo-controlled drug study, assessing contributions of dopamine (400 mg amisulpride) and noradrenaline (40 mg propranolol), we show that value-free random exploration is attenuated under the influence of propranolol, but not under amisulpride. Our findings demonstrate that humans deploy distinct computationally cheap exploration strategies and that value-free random exploration is under noradrenergic control.
Collapse
Affiliation(s)
- Magda Dubois
- Max Planck UCL Centre for Computational Psychiatry and Ageing ResearchLondonUnited Kingdom
- Wellcome Trust Centre for Neuroimaging, University College LondonLondonUnited Kingdom
| | - Johanna Habicht
- Max Planck UCL Centre for Computational Psychiatry and Ageing ResearchLondonUnited Kingdom
- Wellcome Trust Centre for Neuroimaging, University College LondonLondonUnited Kingdom
| | - Jochen Michely
- Max Planck UCL Centre for Computational Psychiatry and Ageing ResearchLondonUnited Kingdom
- Wellcome Trust Centre for Neuroimaging, University College LondonLondonUnited Kingdom
- Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin BerlinBerlinGermany
| | - Rani Moran
- Max Planck UCL Centre for Computational Psychiatry and Ageing ResearchLondonUnited Kingdom
- Wellcome Trust Centre for Neuroimaging, University College LondonLondonUnited Kingdom
| | - Ray J Dolan
- Max Planck UCL Centre for Computational Psychiatry and Ageing ResearchLondonUnited Kingdom
- Wellcome Trust Centre for Neuroimaging, University College LondonLondonUnited Kingdom
| | - Tobias U Hauser
- Max Planck UCL Centre for Computational Psychiatry and Ageing ResearchLondonUnited Kingdom
- Wellcome Trust Centre for Neuroimaging, University College LondonLondonUnited Kingdom
| |
Collapse
|
20
|
Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults. Neurosci Biobehav Rev 2020; 120:123-158. [PMID: 33202256 DOI: 10.1016/j.neubiorev.2020.11.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 10/30/2020] [Accepted: 11/01/2020] [Indexed: 01/08/2023]
Abstract
Dopamine (DA) plays a key role in reward processing and is implicated in psychological disorders such as depression, substance use, and schizophrenia. The role of DA in reward processing is an area of highly active research. One approach to this question is drug challenge studies with drugs known to alter DA function. These studies provide good experimental control and can be performed in parallel in laboratory animals and humans. This review aimed to summarize results of studies using pharmacological manipulations of DA in healthy adults. 'Reward' is a complex process, so we separated 'phases' of reward, including anticipation, evaluation of cost and benefits of upcoming reward, execution of actions to obtain reward, pleasure in response to receiving a reward, and reward learning. Results indicated that i) DAergic drugs have different effects on different phases of reward; ii) the relationship between DA and reward functioning appears unlikely to be linear; iii) our ability to detect the effects of DAergic drugs varies depending on whether subjective, behavioral, imaging measures are used.
Collapse
|
21
|
Soutschek A, Tobler PN. Causal role of lateral prefrontal cortex in mental effort and fatigue. Hum Brain Mapp 2020; 41:4630-4640. [PMID: 32710816 PMCID: PMC7555063 DOI: 10.1002/hbm.25146] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 06/30/2020] [Accepted: 07/08/2020] [Indexed: 11/30/2022] Open
Abstract
Dorsolateral prefrontal cortex (DLPFC) is well‐known for its role in exerting mental work, however the contribution of DLPFC for deciding whether or not to engage in effort remains unknown. Here, we assessed the causal role of DLPFC in effort‐based decision making. We disrupted functioning of DLPFC with noninvasive brain stimulation before participants repeatedly decided whether to exert mental effort in a working memory task. We found the same DLPFC subregion involved in mental effort exertion to influence also effort‐based decisions: First, it enhanced effort discounting, suggesting that DLPFC may signal the capacity to successfully deal with effort demands. Second, a novel computational model integrating the costs of enduring effort into the effort‐based decision process revealed that DLPFC disruption reduced fatigue after accumulated effort exertion, linking DLPFC activation with fatigue. Together, our findings indicate that in effort‐based decisions DLPFC represents the capacity to exert mental effort and the updating of this information with enduring time‐on‐task, informing theoretical accounts on the role of DLPFC in the motivation to exert mental effort and the fatigue arising from it.
Collapse
Affiliation(s)
- Alexander Soutschek
- Department for Psychology, Ludwig Maximilian University Munich, Munich, Germany
| | - Philippe N Tobler
- Zurich Center for Neuroeconomics, Department of Economics, University of Zurich, Zurich, Switzerland.,Neuroscience Center Zurich, University of Zurich, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland
| |
Collapse
|
22
|
Kozak R, Kiss T, Dlugolenski K, Johnson DE, Gorczyca RR, Kuszpit K, Harvey BD, Stolyar P, Sukoff Rizzo SJ, Hoffmann WE, Volfson D, Hajós M, Davoren JE, Abbott AL, Williams GV, Castner SA, Gray DL. Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation. Front Pharmacol 2020; 11:1005. [PMID: 32733245 PMCID: PMC7358525 DOI: 10.3389/fphar.2020.01005] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/22/2020] [Indexed: 12/16/2022] Open
Abstract
Selective activation of dopamine D1 receptors remains a promising pro-cognitive therapeutic strategy awaiting robust clinical investigation. PF-6142 is a key example from a recently disclosed novel series of non-catechol agonists and partial agonists of the dopamine D1/5 receptors (D1R) that exhibit pharmacokinetic (PK) properties suitable for oral delivery. Given their reported potential for functionally biased signaling compared to known catechol-based selective agonists, and the promising rodent PK profile of PF-6142, we utilized relevant in vivo assays in male rodents and male and female non-human primates (NHP) to evaluate the pharmacology of this new series. Studies in rodents showed that PF-6142 increased locomotor activity and prefrontal cortex acetylcholine release, increased time spent in wakefulness, and desynchronized the EEG, like known D1R agonists. D1R selectivity of PF-6142 was supported by lack of effect in D1R knock-out mice and blocked response in the presence of the D1R antagonist SCH-23390. Further, PF-6142 improved performance in rodent models of NMDA receptor antagonist-induced cognitive dysfunction, such as MK-801-disrupted paired-pulse facilitation, and ketamine-disrupted working memory performance in the radial arm maze. Similarly, PF-6142 reversed ketamine-induced deficits in NHP performing the spatial delayed recognition task. Of importance, PF-6142 did not alter the efficacy of risperidone in assays predictive of antipsychotic-like effect in rodents including pre-pulse inhibition and conditioned avoidance responding. These data support the continued development of non-catechol based D1R agonists for the treatment of cognitive impairment associated with brain disorders including schizophrenia.
Collapse
Affiliation(s)
- Rouba Kozak
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Tamás Kiss
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Keith Dlugolenski
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - David E Johnson
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | | | - Kyle Kuszpit
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Brian D Harvey
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Polina Stolyar
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | | | | | - Dmitri Volfson
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| | - Mihaly Hajós
- Global Research and Development, Pfizer Inc., Groton, CT, United States.,Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | | | - Amanda L Abbott
- Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | - Graham V Williams
- Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | - Stacy A Castner
- Department of Comparative Medicine, Yale School of Medicine, New Haven, CT, United States
| | - David L Gray
- Global Research and Development, Pfizer Inc., Groton, CT, United States
| |
Collapse
|